Vor Bio To Participate in Upcoming September Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vor Bio (Nasdaq: VOR) announced management participation in several September 2026 investor events, including the Wells Fargo Healthcare Conference on September 8 (8:00AM ET), Citi’s Biopharma Back to School Conference on September 9 (11:20AM ET), Morgan Stanley’s Global Healthcare Conference on September 14, Baird’s Global Healthcare Conference on September 15 (9:05AM ET), and Stifel’s Virtual Immunology and Inflammation Forum on September 23 (11:30AM ET). A live webcast and 30-day replay of presentations will be available on Vor Bio’s investor relations website.
Details
News Market Reaction – VOR
On Sep 1, the day this news came out, VOR closed 0.71% above the previous close. Argus tracked a peak move of +5.3% during that session. Our momentum scanner recorded 50 alerts in the available session data. Relative volume reached 2.0x the daily average during tracking.
Data tracked by StockTitan Argus for the Sep 1 session.
Key Figures
- Wells Fargo conference date
- September 8th
- 21st Annual Healthcare Conference Forum
- Citi conference date
- September 9th
- 2026 Biopharma Back to School Conference Forum
- Morgan Stanley conference date
- September 14th
- 24th Annual Global Healthcare Conference Forum
- Baird conference date
- September 15th
- 2026 Global Healthcare Conference Forum
- Stifel forum date
- September 23rd
- 2026 Virtual Immunology and Inflammation Forum
- Webcast replay availability
- approximately 30 days
- Following the presentation
Historical Context
-
Phase 3 enrollment continued, with projected funding into early 2029.
-
Equity awards were granted to five newly hired employees.
-
David Zaccardelli joined the board as global Phase 3 development advanced.
-
Equity awards were granted to seven newly hired employees.
-
China's NMPA approved telitacicept for adult Sjögren’s disease.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that management will participate in the following investor conferences:
- Wells Fargo 21st Annual Healthcare Conference
Forum: Fireside Chat and 1x1 Meetings
Date: Tuesday, September 8th
Presentation Time: 8:00AM ET
- Citi’s 2026 Biopharma Back to School Conference
Forum: Fireside Chat and 1x1 Meetings
Date: Wednesday, September 9th
Presentation Time: 11:20AM ET
- Morgan Stanley 24th Annual Global Healthcare Conference
Forum: 1x1 Meetings
Date: Monday, September 14th
- Baird’s 2026 Global Healthcare Conference
Forum: Presentation and 1x1 Meetings
Date: Tuesday, September 15th
Presentation Time: 9:05AM ET
- Stifel’s 2026 Virtual Immunology and Inflammation Forum
Forum: Presentation and 1x1 Meetings
Date: Wednesday, September 23rd
Presentation Time: 11:30AM ET
A live webcast of the presentation may be accessed on the Investors section of the Vor website at ir.vorbio.com. A replay of the webcast will be available on the Vor website for approximately 30 days following the presentation.
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com. Vor Bio routinely posts information that may be important to investors in the “Investors” section of its website. The Company encourages investors to consult that section of its website regularly.

Media & Investor Contacts: Carl Mauch cmauch@vorbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.